{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T05:58:22Z","timestamp":1712037502775},"reference-count":33,"publisher":"RCN Publishing Ltd.","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,1,4]]},"DOI":"10.7748\/ns.2022.e11959","type":"journal-article","created":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T10:00:12Z","timestamp":1667815212000},"page":"61-66","source":"Crossref","is-referenced-by-count":1,"title":["Safe use of sodium glucose co-transporter 2 inhibitors in the management of type 2 diabetes"],"prefix":"10.7748","volume":"38","author":[{"given":"Georgia","family":"Noble-Bell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Comfort","family":"Bright-Davies","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4499","published-online":{"date-parts":[[2022,11,7]]},"reference":[{"issue":"Suppl 1","key":"key20221230070218_R1","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.2337\/dc14-S081","article-title":"Diagnosis and classification of diabetes mellitus","volume":"37","author":"American Diabetes Association","year":"2014","journal-title":"Diabetes Care"},{"issue":"5-6","key":"key20221230070218_R2","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1177\/2042018816676239","article-title":"The renal effects of SGLT2 inhibitors and a mini-review of the literature","volume":"7","year":"2016","journal-title":"Therapeutic Advances in Endocrinology and Metabolism"},{"key":"key20221230070218_R3","unstructured":"Association of British Clinical Diabetologists (2016) SGLT-2 Inhibitors in People with Type 2 Diabetes: An Educational Resource for Health Professionals. abcd.care\/sites\/abcd.care\/files\/site_uploads\/Resources\/Position-Papers\/SGLT2-inhibitors-ABCD.pdf (Last accessed: 19 October 2022.)"},{"issue":"1","key":"key20221230070218_R4","doi-asserted-by":"crossref","first-page":"61","DOI":"10.7748\/ns.2021.e11709","article-title":"Diabetes mellitus: an overview of the types, symptoms, complications and management","volume":"37","year":"2022","journal-title":"Nursing Standard"},{"issue":"12","key":"key20221230070218_R5","first-page":"2669","article-title":"Management of hyperglycemia in type 2 diabetes: a consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD","volume":"41","year":"2018","journal-title":"Diabetes"},{"issue":"1","key":"key20221230070218_R6","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrneph.2016.170","article-title":"Renal, metabolic and cardiovascular considerations of SGLT2 inhibition","volume":"13","year":"2017","journal-title":"Nature Reviews Nephrology"},{"issue":"1","key":"key20221230070218_R7","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/cen.12119","article-title":"Current level of glycaemic control and its associated factors in patients with type 2 diabetes across Europe: data from the PANORAMA study","volume":"80","year":"2014","journal-title":"Clinical Endocrinology"},{"key":"key20221230070218_R8","unstructured":"European Medicines Agency (2016) SGLT2 Inhibitors. www.ema.europa.eu\/en\/medicines\/human\/referrals\/sglt2-inhibitors (Last accessed: 19 October 2022.)"},{"key":"key20221230070218_R9","doi-asserted-by":"crossref","first-page":"777861","DOI":"10.3389\/fmed.2021.777861","article-title":"Sodium-glucose cotransporter 2 inhibitors mechanisms of action: a review","volume":"8","year":"2021","journal-title":"Frontiers in Medicine"},{"issue":"12","key":"key20221230070218_R10","first-page":"2654.e1","article-title":"SGLT2 inhibitor-associated diabetic ketoacidosis: clinical review and recommendations for prevention and diagnosis","volume":"38","year":"2016","journal-title":"Clinical Therapeutics"},{"issue":"5","key":"key20221230070218_R11","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1007\/s13300-017-0277-0","article-title":"Practical approach to initiating SGLT2 inhibitors in type 2 diabetes","volume":"8","year":"2017","journal-title":"Diabetes Therapy"},{"issue":"15","key":"key20221230070218_R12","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","year":"2020","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"key20221230070218_R13","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/MED.0000000000000311","article-title":"An update on SGLT2 inhibitors for the treatment of diabetes mellitus","volume":"24","year":"2017","journal-title":"Current Opinion in Endocrinology, Diabetes, and Obesity"},{"key":"key20221230070218_R14","unstructured":"Joint British Diabetes Societies for Inpatient Care (2021) The Management of Diabetic Ketoacidosis in Adults. abcd.care\/sites\/abcd.care\/files\/site_uploads\/JBDS_Guidelines_Current\/JBDS_02%20_DKA_Guideline_amended_v2_June_2021.pdf (Last accessed: 19 October 2022.)"},{"key":"key20221230070218_R15","volume-title":"British National Formulary. No. 84","author":"Joint Formulary Committee","year":"2022"},{"issue":"9","key":"key20221230070218_R16","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1007\/s12325-016-0379-5","article-title":"Sodium-glucose cotransporter-2 inhibition and the glomerulus: a review","volume":"33","year":"2016","journal-title":"Advances in Therapy"},{"issue":"17","key":"key20221230070218_R17","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1517\/14656566.2014.968551","article-title":"The potential role of sodium glucose co-transporter 2 inhibitors in combination therapy for type 2 diabetes mellitus","volume":"15","year":"2014","journal-title":"Expert Opinion on Pharmacotherapy"},{"issue":"1","key":"key20221230070218_R18","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S2213-8587(17)30186-9","article-title":"Type 2 diabetes in adolescents and young adults","volume":"6","year":"2018","journal-title":"The Lancet Diabetes & Endocrinology"},{"key":"key20221230070218_R19","unstructured":"Medicines and Healthcare products Regulatory Agency (2016) SGLT2 Inhibitors: Updated Advice on the Risk of Diabetic Ketoacidosis. www.gov.uk\/drug-safety-update\/sglt2-inhibitors-updated-advice-on-the-risk-of-diabetic-ketoacidosis (Last accessed: 19 October 2022.)"},{"key":"key20221230070218_R20","unstructured":"Medicines and Healthcare products Regulatory Agency (2019) SGLT2 Inhibitors: Reports of Fournier\u2019s Gangrene (Necrotising Fasciitis of the Genitalia or Perineum). www.gov.uk\/drug-safety-update\/sglt2-inhibitors-reports-of-fournier-s-gangrene-necrotising-fasciitis-of-the-genitalia-or-perineum (Last accessed: 19 October 2022.)"},{"key":"key20221230070218_R21","unstructured":"Medicines and Healthcare products Regulatory Agency (2020) SGLT2 Inhibitors: Monitor Ketones in Blood During Treatment Interruption for Surgical Procedures or Acute Serious Medical Illness. www.gov.uk\/drug-safety-update\/sglt2-inhibitors-monitor-ketones-in-blood-during-treatment-interruption-for-surgical-procedures-or-acute-serious-medical-illness (Last accessed: 19 October 2022.)"},{"issue":"5","key":"key20221230070218_R22","first-page":"162","article-title":"The SGLT2 Inhibitor \u2013 where are we now?","volume":"21","year":"2017","journal-title":"Journal of Diabetes Nursing"},{"key":"key20221230070218_R23","volume-title":"Technology Appraisal Guidance No. 775","author":"National Institute for Health and Care Excellence","year":"2022"},{"key":"key20221230070218_R24","unstructured":"National Institute for Health and Care Excellence (2022b) Clinical Knowledge Summaries: Diabetes \u2013 Type 2. cks.nice.org.uk\/topics\/diabetes-type-2 (Last accessed: 19 October 2022.)"},{"key":"key20221230070218_R25","volume-title":"NICE guideline No. 28","author":"National Institute for Health and Care Excellence","year":"2022"},{"key":"key20221230070218_R26","unstructured":"National Institute for Health and Care Excellence (2022d) Type 2 Diabetes in Adults: Choosing Medicines. www.nice.org.uk\/guidance\/ng28\/resources\/visual-summary-full-version-choosing-medicines-for-firstline-and-further-treatment-pdf-10956472093 (Last accessed: 19 October 2022.)"},{"issue":"7","key":"key20221230070218_R27","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","year":"2017","journal-title":"New England Journal of Medicine"},{"issue":"25","key":"key20221230070218_R28","first-page":"2295","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","year":"2019","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"key20221230070218_R29","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1530\/EJE-19-0143","article-title":"Lean non-alcoholic fatty liver disease and development of diabetes: a cohort study","volume":"181","year":"2019","journal-title":"European Journal of Endocrinology"},{"key":"key20221230070218_R30","unstructured":"South East London Area Prescribing Committee (2019) South East London Blood Glucose Control Management Pathway for Adults with Type 2 Diabetes Mellitus (T2DM). selondonccg.nhs.uk\/wp-content\/uploads\/dlm_uploads\/2021\/09\/Blood-glucose-control-pathway-type-2-Oct-2019-FINAL.pdf (Last accessed: 19 October 2022.)"},{"key":"key20221230070218_R31","unstructured":"World Health Organization (2022) Diabetes. www.who.int\/news-room\/fact-sheets\/detail\/diabetes (Last accessed: 19 October 2022.)"},{"issue":"1","key":"key20221230070218_R32","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12933-021-01266-x","article-title":"Cardiovascular benefits of sodium-glucose transporter 2 inhibitors in diabetic and nondiabetic patients","volume":"20","year":"2021","journal-title":"Cardiovascular Diabetology"},{"issue":"22","key":"key20221230070218_R33","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","year":"2015","journal-title":"New England Journal of Medicine"}],"container-title":["Nursing Standard"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.rcni.com\/doi\/pdf\/10.7748\/ns.2022.e11959","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T19:57:39Z","timestamp":1705003059000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.rcni.com\/doi\/10.7748\/ns.2022.e11959"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,7]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,11,7]]},"published-print":{"date-parts":[[2023,1,4]]}},"alternative-id":["10.7748\/ns.2022.e11959"],"URL":"https:\/\/doi.org\/10.7748\/ns.2022.e11959","relation":{},"ISSN":["0029-6570","2047-9018"],"issn-type":[{"value":"0029-6570","type":"print"},{"value":"2047-9018","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,7]]}}}